← All trials
NCT04762017
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 11, 2021
- Primary completion
- Aug 25, 2021
- Completion date
- Dec 25, 2022
- First posted
- Feb 21, 2021
- Last posted
- Mar 3, 2021
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Accure TherapeuticsLead sponsor
- Accure TherapeuticsStudy director
- Neurotrials Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.